These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18850562)

  • 21. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Japanese Age-Related Macular Degeneration Tial (JAT) Study Group
    Am J Ophthalmol; 2003 Dec; 136(6):1049-61. PubMed ID: 14644215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
    Larsen M; Schmidt-Erfurth U; Lanzetta P; Wolf S; Simader C; Tokaji E; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):992-1000. PubMed ID: 22424834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Photodynamic therapy.
    Kotoula MG; Tsironi EE; Karabatsas CH; Chatzoulis DZ
    Retina; 2005 Jan; 25(1):102-3. PubMed ID: 15655455
    [No Abstract]   [Full Text] [Related]  

  • 26. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration.
    Ergun E; Maár N; Ansari-Shahrezaei S; Wimpissinger B; Krepler K; Wedrich A; Stur M
    Am J Ophthalmol; 2006 Jul; 142(1):10-16. PubMed ID: 16815246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2.
    Bressler NM
    Am J Ophthalmol; 2002 Jan; 133(1):168-9. PubMed ID: 11755871
    [No Abstract]   [Full Text] [Related]  

  • 28. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.
    Augustin AJ; Schmidt-Erfurth U
    Ophthalmology; 2006 Jan; 113(1):14-22. PubMed ID: 16360209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial.
    Chaudhary V; Mao A; Hooper PL; Sheidow TG
    Ophthalmology; 2007 Dec; 114(12):2183-9. PubMed ID: 18054638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.
    Slakter JS; Bochow TW; D'Amico DJ; Marks B; Jerdan J; Sullivan EK; Robertson SM; Slakter JS; Sullins G; Zilliox P;
    Ophthalmology; 2006 Jan; 113(1):3-13. PubMed ID: 16368146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.
    Heier JS; Boyer DS; Ciulla TA; Ferrone PJ; Jumper JM; Gentile RC; Kotlovker D; Chung CY; Kim RY;
    Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin.
    Houle JM; Strong HA
    Retina; 2002 Dec; 22(6):691-7. PubMed ID: 12476093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
    Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
    Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.
    Blumenkranz MS; Bressler NM; Bressler SB; Donati G; Fish GE; Haynes LA; Lewis H; Miller JW; Monés JM; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Schachat AP; Schmidt-Erfurth U; Sickenburg M; Singerman LJ; Slakter JS; Strong A; Vannier S;
    Arch Ophthalmol; 2002 Oct; 120(10):1307-14. PubMed ID: 12365909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
    Azab M; Boyer DS; Bressler NM; Bressler SB; Cihelkova I; Hao Y; Immonen I; Lim JI; Menchini U; Naor J; Potter MJ; Reaves A; Rosenfeld PJ; Slakter JS; Soucek P; Strong HA; Wenkstern A; Su XY; Yang YC;
    Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Photodynamic therapy with verteporfin for choroidal neovascularization due to age-related macular degeneration and other causes: a New Zealand outcomes study.
    Sharp DM; Lai S; Markey CM
    Clin Exp Ophthalmol; 2007; 35(1):24-31. PubMed ID: 17300567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Photodynamic therapy in age-related macular degeneration--results of one year observation].
    Wykrota H; Gierek-Łapińska A
    Klin Oczna; 2002; 104(3-4):239-43. PubMed ID: 12608309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spotlight on verteporfin in subfoveal choroidal neovascularisation.
    Keam SJ; Scott LJ; Curran MP
    Drugs Aging; 2004; 21(3):203-9. PubMed ID: 14979737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study.
    Arias L; Garcia-Arumi J; Ramon JM; Badia M; Rubio M; Pujol O
    Ophthalmology; 2006 Dec; 113(12):2243-50. PubMed ID: 16996600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.